- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

At CES 2026, Luna has introduced the Luna Band, a screenless fitness wearable positioned as an alternative to ...

Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Adverum's Webcast to discuss the 26-Week Interim Analysis of the ongoing LUNA Phase 2 trial that was presented earlier today ...

(RTTNews) - Adverum Biotechnologies (ADVM) reported results from the 26-week interim analysis of the LUNA Phase 2 trial of Ixo-vec in patients with wet age-related macular degeneration. Adverum said ...

Luna is making like the Phoenix. Luna 2.0, a new Terra Luna token, is set to launch on May 27, rising from the ashes of the spectacular crash that rocked the cryptocurrency market right down to its ...

REDWOOD CITY, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly ...